Lv61
1690 积分 2021-04-08 加入
Trispecific antibodies take to the clinic
4个月前
已完结
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
9个月前
已完结
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
9个月前
已完结
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
10个月前
已完结
Trends in the global immuno-oncology landscape
10个月前
已完结
Controlling the biodistribution and clearance of nanomedicines
1年前
已完结
Analysis of nanoparticle delivery to tumours
1年前
已完结
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
1年前
已完结
Bispecific antibodies for cancer therapy: A review
2年前
已完结
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
3年前
已完结
皖公网安备34019202002308
